Please login to the form below

Not currently logged in

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

Roche’s Tecentriq has demonstrated positive data in early stage non-small cell lung cancer (NSCLC) at a phase 3 interim analysis.

In the phase 3 IMpower010 study, Tecentriq (atezolizumab) demonstrated a statistically significant improvement in disease-free survival (DFS) as an adjuvant therapy, after surgery and chemotherapy, in all randomised populations with early stage NSCLC.

Although Roche did not disclose the detailed results, the Swiss pharma company added that the magnitude of DFS benefit was ‘particularly pronounced’ in the PD-L1-positive population.

Roche will continue to evaluate Tecentriq in the overall intent-to-treat population, which did not cross the threshold at the time of analysis.

Another planned analysis will also review overall survival data, as this was immature at the time of interim analysis.

“With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning," said Levi Garraway, chief medical officer and head of global product development at Roche.

“We’re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. We will submit this data to regulatory authorities as soon as possible,” he added.

Tecentriq is already currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the dominant shadow of Merck & Co’s Keytruda (pembrolizumab).

Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC.

SCLC is less common than NSCLC but tends to be more aggressive, growing more quickly and spreading to other parts of the body earlier. The five-year survival rate with this form of cancer is as low as 6%, with two-thirds of patients having advanced disease at the time of diagnosis.

In addition to its SCLC approval, Tecentriq is also approved in four NSCLC indications, as either a single agent or in combination with targeted therapies and chemotherapies.

In January, Roche also received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for a combination of its investigational TIGIT blocker tiragolumab and Tecentriq (atezolizumab) for the first-line treatment of certain metastatic NSCLC patients.

Article by
Lucy Parsons

22nd March 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....